$ 111.15
Key Takeaways
Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is reasonably priced on P/E, 'expensive'
Target Price
The average target price of GILD is 118 and suggests 7% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
